The American Psychological Association Practice Organization is an affiliate of the American Psychological Association, the largest scientific organization and professional organization the psychology in the United States. APA membership includes more than 155,000 researchers, educators, consultants and students.
A Tel Aviv start Ester Neurosciences was the of the promising technology of Prof. Soreq by developing a drug to block production of the ACHE protein in patients with muscle – weakening disease developed based use.Nectars assumes no obligation looking statements-looking statements, whether as a result of new information, future events or otherwise.. This press release includes forward-looking statements, challenges of nectars current views in the potential, progress, and clinical plans to NKTR-102 and of the value and potential on nectar adapt progressive polymer conjugate deck. These forwardlooking statements entail risks and uncertainties, including, but is not limited: NKTR-102 is in the earlier stages clinical trials and to the risk the failure is high and can occur unexpectedly, timing of the start or at the the clinical trials delayed or inability because slower than anticipated patient receiving, pharmaceutical manufacturing challenges, changing standards of nursing, clinical trials style, and unanticipated clinical results, clinical trials are long, expensive and uncertain process and the risk of failure a product candidate to being in the of early clinical development remained high and may be unexpectedly due to at any stage, to evaluate the efficacy, security , or other factors occur, the nectar of Patent Application for its proprietary or partner product candidate able not grant, patent, of new information have issued be unenforceable and intellectual property licenses may of third parties in future in the future, and .
12 months 2 studies in ovarian, breast and cervical cancer be open, single arm studies involves two treatment regimens . Patients include those having from metastatic breast cancer with previous taxane is the treatment, those with metastasized, board – resistant ovarian cancer and those with a metastatic cervical cancer. The attempts are designed to determine the total response evaluate rate by NKTR-102 monotherapy for every tumor setting, having secondary endpoint including progression-free survival, certainty to six and 12-month survival rates..